Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Altered adipose lipid mobilization predicts long-term weight gain and impaired glucose metabolism

ABSTRACT: Altered adipose lipid mobilization predicts long-term weight gain and impaired glucose metabolism

PROVIDER: PRJNA449938 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Altered adipose lipid mobilization predicts long-term weight gain and impaired glucose metabolism

Project description:Factors predicting body weight gain and associated disturbed glucose metabolism remain to be established. Here we assessed the role of subcutaneous adipocyte lipid mobilization (lipolysis) in spontaneous long-term (>10 years) body weight changes. In two independent clinical cohorts we found that low stimulated lipolysis at baseline correlated inversely with body mass index changes over time. Disturbed lipolysis gave odds ratios of ≥4.6 for weight gain and ≥3.2 for development of insulin resistance and impaired fasting glucose/type 2 diabetes. Baseline adipose mRNA expression of a set of established lipolysis-regulating genes was lower in weight gainers.

2018-04-13 | GSE113080 | GEO

Antipsychotic Weight Gain

Project description:Altered Gene Expression in Antipsychotic Induced Weight Gain

| PRJEB31532 | ENA

Prognostic biomarkers of antipsychotic-induced weight gain

Project description:Prognostic biomarkers of antipsychotic-induced weight gain

| PRJNA661304 | ENA

Prognostic biomarkers of antipsychotic-induced weight gain

Project description:Antipsychotic drugs (APs) are used to treat psychiatric disorders but also have the prominent side effect of weight gain resulting in a higher incidence of metabolic disease in this patient group. While the majority of patients gain significant weight in response to APs some patients are relatively resistant to these effects. APs such as clozapine and olanzapine are deemed to be highly efficacious at treating psychiatric conditions yet they have some of the highest weight gain liabilities. Therefore, there is a need to determine which patients are less susceptible to the metabolic side effects of APs and would be good candidates for drugs such as olanzapine, and conversely, identifying patients that should be prescribed alternative APs with less weight gain liabilities.

2021-01-01 | GSE157438 | GEO

Protection against overfeeding-induced weight gain in mice is preserved in obesity but does not require FGF21 or MC4R

Project description:Experimental overfeeding triggers homeostatic compensatory mechanisms that counteract weight gain. Here, we utilized intragastric overfeeding in mice to investigate the physiological and molecular responses to forced weight gain. Both lean and diet-induced obese (DIO) mice exhibited a potent and prolonged lowering of voluntary food intake following overfeeding-induced weight gain. Although overfeeding resulted in a marked increase in circulating fibroblast growth factor 21 (FGF21), experiments with FGF21 knockout (KO) mice demonstrated that FGF21 is dispensable for the homeostatic defense against experimental weight gain. Targeted proteomics unveiled novel circulating factors linked to overfeeding, including the protease legumain (LGMN). Notably, administration of recombinant LGMN lowered body weight and food intake in DIO mice. The protection against weight gain was also associated with reduced vascularization in the hypothalamus and sustained reductions in transcript levels of the orexigenic neuropeptides, Npy and AgRP, suggesting a role of hypothalamic signaling in the homeostatic recovery from overfeeding. Overfeeding of melanocortin 4 receptor (MC4R) KO mice showed that these mice can suppress voluntary food intake and counteract the enforced weight gain, although their rate of weight recovery is impaired. Collectively, these findings demonstrate that the defense against overfeeding-induced weight gain remains intact in obesity and involves mechanisms independent of both FGF21 and MC4R.

2024-01-12 | GSE247825 | GEO

Integrative Personal Omics Profiles During Periods of Weight Gain and Loss

Project description:A longitudinal study of PBMCs from patients during periods of weight gain and loss in humans was performed.

2018-01-11 | PXD007859 | Pride

A BAFF/APRIL axis regulates obesogenic-diet driven weight gain

Project description:A BAFF/APRIL axis regulates obesogenic-diet driven weight gain

| PRJNA543147 | ENA

The host & gut microbiome orchestrate smoking cessation-induced weight gain

Project description:The host & gut microbiome orchestrate smoking cessation-induced weight gain

| PRJEB47053 | ENA

Weight gain and loss induce changes in luteal molecular signals in vervet monkeys

Project description:Weight gain and loss did not significantly alter menstrual cyclicity, however, both induced alterations in the CL transcriptome

2016-05-01 | GSE77827 | GEO

The host & gut microbiome orchestrate smoking cessation-induced weight gain

Project description:To elucidate the potential impact of smoking cessation weight gain associated metabolites on adipose tissue cellular and gene-expression immune program, we performed single cell transcriptomic analysis of immune cells of epididymal adipose tissue in DMG- and ACG-supplemented mice and their respective non-supplemented controls

2021-11-22 | E-MTAB-10869 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data